Hepatitis C Virus is a viral infection that causes liver inflammation, sometimes leading to serious liver damage. It is caused by the hepatitis C virus (HCV) and is a major cause of liver cancer.
The total prevalent cases of Hepatitis C Virus in the 7MM was 8,257,162 in 2017. The prevalent cases of HCV in the US was 3,251,471.
As per the Delveinsight, the therapeutic market of Hepatitis C Virus in the 7MM was found to be USD 10,445 million in 2017, which is expected to increase during the forecast period.
The key companies in the Hepatitis C Virus market include Cocrystal Pharma, Atea Pharmaceuticals, PRISM Pharma, Ohara Pharmaceuticals, GeneCure Biotechnologies, and others.